文献速递角膜与眼表疾病

鼻内神经刺激治疗干眼症的安全性与有效性随机对照试验

Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

这项多中心、随机、对照、双盲预试验评估了鼻内神经刺激促进干眼症患者泪液分泌的安全性和有效性。第90天活性组刺激诱导的Schirmer评分变化(9.0±2.0)显著大于假对照组(0.4±0.6,P<0.001),无严重器械相关不良事件,最常见为轻度鼻出血(16.7%)。

要点

  • 鼻内神经刺激在第90天显著增加干眼症患者的刺激诱导Schirmer评分。
  • 第0、7、14、30天也观察到类似显著差异(P<0.001)。
  • 无严重器械相关不良事件,轻度鼻出血发生率为16.7%。

核心结论

  • 鼻内神经刺激使用90天后能有效诱导急性泪液分泌,且在干眼症患者中总体耐受良好。

主要发现

  • 第90天活性鼻内刺激组刺激诱导的Schirmer评分变化均值±标准误为9.0±2.0,假对照组为0.4±0.6,组间差异显著(P<0.001)。
  • 第0、7、14、30天也观察到类似显著结果(P<0.001)。
  • 未观察到严重器械相关不良事件;轻度鼻出血是最常见的器械相关不良事件,报告于5名(16.7%)受试者。

关键数值与推荐

  • 纳入标准包括干眼诊断且至少一眼角膜荧光素染色至少一个区域≥2或所有区域总和≥5(国家眼科研究所分级),基础Schirmer试验评分≤10 mm,棉签刺激后Schirmer评分增加≥7 mm,眼表疾病指数评分≥23。
  • 主要有效性终点为刺激诱导的Schirmer试验(麻醉后)评分变化;主要安全性指标为器械相关不良事件发生率。

临床怎么用

  • 鼻内神经刺激可作为干眼症促进泪液分泌的一种治疗选择,使用90天可诱导急性泪液分泌且耐受性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assess the safety and effectiveness of intranasal neurostimulation to promote tear production via the nasolacrimal pathway in subjects with dry eye disease. METHODS: A multicenter, randomized, controlled, double-masked pilot study was conducted in adults with dry eye diagnosis and at least one eye with corneal fluorescein staining ≥2 in at least one region or a sum of all regions ≥5 (National Eye Institute grading), basal Schirmer test score ≤10 mm, a cotton-swab stimulated Schirmer score ≥7 mm higher, and an Ocular Surface Disease Index score ≥23. Subjects were randomized to receive active intranasal neurostimulation or sham control intranasal stimulation 4 to 8 times per day. Assessments were scheduled before (unstimulated) and during (stimulated) device application at days 0, 7, 14, 30, and 90. The primary effectiveness endpoint was stimulation-induced change in Schirmer test (with anesthesia) score. Primary safety measure was incidence of device-related adverse events (AEs). RESULTS: Fifty-eight subjects were randomized at nine sites in Australia and New Zealand; 56 completed the 90-day study. Stimulation-induced change in Schirmer score was significantly greater with active intranasal (mean ± SEM, 9.0 ± 2.0) than sham control intranasal stimulation (0.4 ± 0.6; P < 0.001) at day 90. Similar results were observed at days 0, 7, 14, and 30 (P < 0.001). No serious device-related AEs were observed. Mild nosebleed, the most common device-related AE, was reported in five (16.7%) subjects. CONCLUSIONS: Intranasal neurostimulation was effective in inducing acute tear production after 90 days of use and generally was well tolerated in subjects with dry eye disease.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Cohn GS, Corbett D, Tenen A, et al. Randomized, Controlled, Double-Masked, Multicenter, Pilot Study Evaluating Safety and Efficacy of Intranasal Neurostimulation for Dry Eye Disease. Invest Ophthalmol Vis Sci. 2019. PMID: 30629728. doi:10.1167/iovs.18-23984

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。